You made the post where is it ?
Truth is You removed the TA top prediction you made a few days ago that was above today's 17.67 call
Weak at best
With that Analogy don't invest more than YOU can afford to lose *
You Girls can't spot a " Coiled Spring " ?
Or the obvious
Come on now your........... groupies have inquiring interest *
You just validated my point TA thrown out because ( Your words now ) .....I do not play these because I can not see these.
Now you and your sister have said TA will give you the levels for our nextCAT event but have avoided giveing them for some reason you choose to dance around it with Old tired Bla Bla Bla *
The most frequently reported local reaction was injection site pain. The most common systemic reactions were fatigue, headache and malaise, all of which were similar to an existing vaccine.
Dynavax has worldwide commercial rights to HEPLISAV-B.
As of June 30, 2016, there were 38,497,107 shares of our common stock outstanding.
On November 12, 2015, we entered into an At Market Issuance Sales Agreement (the “2015 ATM Agreement”) with Cowen under which we could offer and sell our common stock from time to time up to aggregate sales proceeds of $90 million through Cowen as our sales agent. As of June 30, 2016, we have sold NO shares of common stock under the 2015 ATM Agreement.
Preparations for launch of HEPLISAV-B are continuing, including pre-commercial activities, manufacturing of launch inventory and continued infrastructure spending related to implementation of commercial development and information technology systems and capabilities and related increases in headcount.
Research and development expense s for the second quarter of 2016 were $22.8 million compared to $19.7 for the same period in 2015. This $3.1 million increase was primarily due to an increase in employee headcount and regulatory and manufacturing activities in preparation for the anticipated commercial launch of H EPLISAV -B , partially offset by a reduction in outside services expense associated with the completion of HBV-23 in the fourth quarter of 2015
General and administrative expenses for the second quarter of 2016 were $9.2 million compared to $5.1 for the same period in 2015. This $4.1 million increase reflects expenses related to preparation for the commercial launch of HEPLISAV-B including additional headcount, information technology systems and infrastructure to support commercial development.
Products Advisory Committee (VRBPAC) is scheduled to discuss HEPLISAV-B at its meeting on (November 16, 2016). The FDA has indicated it will communicate questions for the VRBPAC to address closer in time to the meeting date.
How out of line would it be to build such an expensive CART
They must have some REAL CONFIDENCE in their HORSE
How ironic November 15 last ( VRBPAC )
In Phase 3 trials, HEPLISAV-B demonstrated higher and earlier protection with fewer doses than a currently licensed hepatitis B vaccine. It also demonstrated a similar safety profile to the existing vaccine
The investigational vaccine's safety profile is based on clinical trials that generated safety data from more than 14,000 participants. The most frequently reported local reaction was injection site pain. The most common sy
Dynavax Technologies Corporation highlighted data from two phase 3 studies of its investigational vaccine HEPLISAV, one of which was the first clinical trial to prospectively evaluate the effectiveness of vaccinations with recombinant hepatitis B vaccines in patients diagnosed with diabetes. The data for both studies demonstrated that HEPLISAV provides faster, more robust and convenient, and longer-lasting immunity in persons with diabetes than a currently available vaccine, Engerix-B. Also today, the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend that hepatitis B vaccine should be administered to unvaccinated adults with diabetes who are less than 60 years of age. Of the 218 subjects with diabetes in the MITT population (179 HEPLISAV; 39 Engerix-B), the seroprotection rates (SPRs) for HEPLISAV were superior to Engerix-B at Weeks 8 through 52. -- At the pre-specified primary comparison time points of Week 12 for HEPLISAV and Week 32 for Engerix-B, the SPR was 79% in the HEPLISAV group and 61% in the Engerix-B group. At Week 12, the SPR was 79% in the HEPLISAV group and 11% in the Engerix-B group. At Week 52, the SPR was 82% in the HEPLISAV group and 54% in the Engerix-B group.
The conservative estimate of peak sales would be around 450 million (in the US alone) with the company having free cash of 100 million by the end of this year. Going with a very conservative x3 multiple for the industry I would place a price target $35/share for potential revenue and $8/share for free cash giving a price target of $43/share at year's end. Assuming the vaccine only gets approved for diabetics, peak sales could reach a population of 2 million diabetics annually.
It's understandable Why you don't post your buy Price, No one would be able to critique the trade.
For someone that Thinks he's teaching others " How to " optimize the trade you leave out 50 % of your actual transaction detail in real time.
You Post only the sell as if others can see some REAL TRUTH in that.
SORRY. THIS IS THE REAL BS *
Jimmy you remind me of a fella I fished a tournament with.
It was on a river and was a catch and release, so to verify
Your catch you took a picture of it next to a tape. Now I
Know this guy and he would never cheat he's a stand up guy
BUT he took a picture of what would have been the winning Trout
That only showed the fish from about the middle of it out to the
end of the tape.
No one could verify the TRUTH * and it was disqualified.